FIELD: biotechnology; medicine.
SUBSTANCE: kit is proposed for the detection of cervical cancer using CG identifier (CGID) methylation analysis via bisulfite sequencing with multiplex targeted amplification. The specified kit includes the reagents necessary to perform the specified CGID assay with SEQ ID NO: 3 and 31 and measuring their methylation levels.
EFFECT: expanding the scope of DNA methylation biomarkers for the early detection of cervical cancer.
3 cl, 8 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED PURIFICATION AND MEASUREMENT OF DNA METHYLATION WITH COMBINED MEASUREMENT OF MUTATIONS AND/OR LEVELS OF mRNA EXPRESSION IN AUTOMATED REACTION CARTRIDGE | 2017 |
|
RU2780660C2 |
| REAGENT FOR DETECTION, A KIT FOR DETECTING AND A METHOD FOR DETECTING METHYLATION OF THE ITGA4 GENE | 2017 |
|
RU2739071C1 |
| SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENTLY LABELLED PROBES FOR IDENTIFYING THE EPIGENETIC MARKERS OF CERVICAL CANCER | 2021 |
|
RU2760573C1 |
| URINE BIOMARKER COHORTS, GENE EXPRESSION SIGNATURES AND METHODS OF USE THEREOF | 2014 |
|
RU2668164C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| MODIFIED CLOSED-ENDED DNA (scDNA) | 2018 |
|
RU2800026C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| DOSING REGIMEN OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN A COMBINATION | 2018 |
|
RU2767533C2 |
| MODIFIED ANTIGEN-BINDING MOLECULES WITH CHANGED CELL SIGNAL ACTIVITY | 2006 |
|
RU2547931C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
